Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30934837 | 1.00 | MAPT (0.35) | MAPTMEN1KMT2AHASPINPOLB | |
| SCHEMBL1506443 | 0.83 | MAPT (0.39) | MAPTMEN1KMT2APOLB | |
| SCHEMBL1506526 | 0.81 | KMT2A (0.41) | MAPTMEN1KMT2APOLB | |
| SCHEMBL30934943 | 0.81 | KMT2A (0.41) | MAPTMEN1KMT2APOLB | |
| SCHEMBL3572773 | 0.75 | MEN1 (0.36) | MEN1KMT2AHASPINPOLB | |
| SCHEMBL18232261 | 0.75 | HASPIN (0.37) | MEN1KMT2AHASPINPOLB | |
| Hydrochloric Acid SCHEMBL3582645 | 0.74 | MEN1 (0.35) | MEN1KMT2AHASPIN | |
| SCHEMBL4693682 | 0.74 | MEN1 (0.35) | MEN1KMT2AHASPINPOLB | |
| SCHEMBL19744259 | 0.74 | MAPT (0.39) | MAPTMEN1KMT2APOLB | |
| SCHEMBL30934714 | 0.74 | MAPT (0.39) | MAPTMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-09 | — | — | US | disclosed |
| US-20190233426-A1 | IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-08-01 | — | — | US | disclosed |
| EP-3472166-A1 | IMIDAZOPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER | Novartis AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017221100-A1 | IMIDAZOPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233426-A1 | IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, BMI1 | MAPT 877/4885MEN1 630/4885KMT2A 31/4885 |
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | EZH2, DOT1L, BMI1 | MAPT 877/4885MEN1 630/4885KMT2A 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.